/
Navigation
Chronicles
Browse all articles
Explore
Semantic exploration
Research
Entity momentum
Nexus
Correlations & relationships
Story Arc
Topic evolution
Drift Map
Semantic trajectory animation
Posts
Analysis & commentary
Pulse API
Tech news intelligence API
Browse
Entities
Companies, people, products, technologies
Domains
Browse by publication source
Handles
Browse by social media handle
Detection
Concept Search
Semantic similarity search
High Impact Stories
Top coverage by position
Sentiment Analysis
Positive/negative coverage
Anomaly Detection
Unusual coverage patterns
Analysis
Rivalry Report
Compare two entities head-to-head
Semantic Pivots
Narrative discontinuities
Crisis Response
Event recovery patterns
Connected
Search: /
Command: ⌘K
Embeddings: large
TEXXR

Chronicles

The story behind the story

days · browse · Enter similar · o open

How routine drug use by Silicon Valley executives moved from an after-hours activity squarely into corporate culture, causing issues for boards and tech leaders

Entrepreneurs including Elon Musk and Sergey Brin are part of a drug movement that proponents hope will expand minds, enhance lives and produce business breakthroughs

Wall Street Journal

Context & Ripple Effects

The coverage places executive drug use in a broader shift from private Silicon Valley social circles to a governance issue. Earlier reporting described drug-fueled gatherings among influential entrepreneurs and investors, while this account connects the culture to leaders running consequential companies.

Later reporting made the governance concern more concrete: directors at Tesla and SpaceX were reportedly worried about the potential effect of Musk's drug use on his companies, and some directors reportedly felt pressure around participation, raising questions about board independence.

First-order effects

  • Boards and senior leaders must treat executives' drug use as a corporate-risk and oversight matter rather than solely a private conduct issue.
  • For companies associated with Elon Musk and other prominent executives, the reported culture puts director independence and leadership judgment under closer scrutiny.

Second-order effects

  • Board nomination, compliance, and risk processes face pressure to distinguish social proximity to a powerful founder from independent oversight.
  • The issue can raise the reputational and governance burden for companies whose investor confidence depends heavily on a small number of high-profile leaders.

Third-order effects

  • If this pattern persists, founder-led tech companies may face a sharper transition from informal, personality-driven norms toward institutional governance standards.
  • The durable question is whether boards can remain credible monitors when the social culture around a dominant executive overlaps with the boardroom.

The trend: This is one instance of the strategic-institution transition, in which founder-centric tech cultures encounter the governance demands of larger, more consequential companies.

Discussion

  • @nycsouthpaw @nycsouthpaw on x
    I wonder what it would be like to get a lede like this past a newsroom legal review intact. https://www.wsj.com/... [image]
  • @bendreyfuss Ben Dreyfuss on x
    The WSJ is such a weird compendium of competing ideas because it's like: “TECH GIANTS ARE DRUG ADDICTS” But “CITIES ARE RIFE WITH DRUG FUELED CRIMES” And the opinion page is all “TECH BILLIONAIRES ARE SMARTER THAN YOU THINK” But “EXECUTE FENTANYL ADDICTS” https://twitter.com/...
  • @sspencer_smb Steven Spencer on x
    Elon Musk takes ketamine. Sergey Brin sometimes consumes magic mushrooms. They are part of a drug movement across the tech industry that proponents hope will expand minds, enhance lives and produce business breakthroughs. https://www.wsj.com/... via @WSJ
  • @mattyglesias Matthew Yglesias on x
    I guess this is a banal explanation for some of the erratic behavior we are seeing https://twitter.com/...
  • @davecbenoit Dave Benoit on x
    The Electric Kool-Aid Ketamine Test: Silicon Valley convinces themselves they know how to use drugs for “business.” ⁦By @KirstenGrind⁩ ⁦⁦@katiebindley⁩ https://www.wsj.com/...
  • @mroliverbarnes Oliver Barnes on x
    Elon Musk has told people he microdoses ketamine for depression, and he also takes full doses of ketamine at parties, according to the people who have witnessed his drug use and others who have direct knowledge of it. https://www.wsj.com/...
  • @karaswisher Kara Swisher on x
    I wrote about this growing trend of psychedelic use back in 2018 — which was seen as a way for techies to expand their minds in the style of Steve Jobs. The issue today is that use by some leaders is now so excessive that it's curdled those brains. It has. https://www.wsj.com/...